Literature DB >> 21350367

The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients.

Sarah W Read1, Emily J Ciccone, Peter J Mannon, Michael D Yao, Cheryl L Chairez, Richard T Davey, Joseph A Kovacs, Irini Sereti.   

Abstract

We sought to determine the effects of interleukin-2 administered in combination with antiretroviral therapy (ART) on CD4+ T cells in the gut. Lymphocytes from whole blood, colon, and terminal ileum of HIV-infected adults treated with interleukin-2 and ART or ART alone were examined. There were no differences between groups in the proportion of CD4+ T cells or in expression of CD25 or Ki67 by CD4+ T cells in the gut. Although IL-2 administration leads to expansion of peripheral blood CD4+ T cells, there is no alteration in the proportion or activation of CD4+ T cells in the gut mucosa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21350367      PMCID: PMC3073743          DOI: 10.1097/QAI.0b013e31820bf84c

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  20 in total

1.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.

Authors:  R S Veazey; M DeMaria; L V Chalifoux; D E Shvetz; D R Pauley; H L Knight; M Rosenzweig; R P Johnson; R C Desrosiers; A A Lackner
Journal:  Science       Date:  1998-04-17       Impact factor: 47.728

2.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

3.  Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

Authors:  Y Levy; C Capitant; S Houhou; I Carriere; J P Viard; C Goujard; J A Gastaut; E Oksenhendler; L Boumsell; E Gomard; C Rabian; L Weiss; J G Guillet; J F Delfraissy; J P Aboulker; M Seligmann
Journal:  Lancet       Date:  1999-06-05       Impact factor: 79.321

4.  Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.

Authors:  Joseph A Kovacs; Richard A Lempicki; Igor A Sidorov; Joseph W Adelsberger; Irini Sereti; William Sachau; Grace Kelly; Julia A Metcalf; Richard T Davey; Judith Falloon; Michael A Polis; Jorge Tavel; Randy Stevens; Laurie Lambert; Douglas A Hosack; Marjorie Bosche; Haleem J Issaq; Stephen D Fox; Susan Leitman; Michael W Baseler; Henry Masur; Michele Di Mascio; Dimiter S Dimitrov; H Clifford Lane
Journal:  J Clin Invest       Date:  2005-07-14       Impact factor: 14.808

5.  A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.

Authors:  R T Davey; D G Chaitt; J M Albert; S C Piscitelli; J A Kovacs; R E Walker; J Falloon; M A Polis; J A Metcalf; H Masur; R Dewar; M Baseler; G Fyfe; M A Giedlin; H C Lane
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

6.  Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.

Authors:  Moraima Guadalupe; Elizabeth Reay; Sumathi Sankaran; Thomas Prindiville; Jason Flamm; Andrew McNeil; Satya Dandekar
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.

Authors:  J A Kovacs; S Vogel; J M Albert; J Falloon; R T Davey; R E Walker; M A Polis; K Spooner; J A Metcalf; M Baseler; G Fyfe; H C Lane
Journal:  N Engl J Med       Date:  1996-10-31       Impact factor: 91.245

Review 8.  Interleukin-2: inception, impact, and implications.

Authors:  K A Smith
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

9.  IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation.

Authors:  Irini Sereti; Kara B Anthony; Hector Martinez-Wilson; Richard Lempicki; Joseph Adelsberger; Julia A Metcalf; Claire W Hallahan; Dean Follmann; Richard T Davey; Joseph A Kovacs; H Clifford Lane
Journal:  Blood       Date:  2004-04-13       Impact factor: 22.113

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  4 in total

Review 1.  Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Authors:  Sheila M Keating; Evan S Jacobs; Philip J Norris
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

2.  Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults.

Authors:  Steven A Yukl; Amandeep K Shergill; Valerie Girling; Qingsheng Li; Maudi Killian; Lorrie Epling; Peilin Li; Philipp Kaiser; Ashley Haase; Diane V Havlir; Kenneth McQuaid; Elizabeth Sinclair; Joseph K Wong
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

3.  Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.

Authors:  Norman Markowitz; Gustavo Lopardo; Deborah Wentworth; Daniela Gey; Abdel Babiker; Lawrence Fox; Jorge Tavel
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

4.  Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration.

Authors:  Irini Sereti; Jacob D Estes; William L Thompson; David R Morcock; Margaret A Fischl; Thérèse Croughs; Stéphanie Beq; Sylvie Lafaye de Micheaux; Michael D Yao; Alexander Ober; Eleanor M P Wilson; Ven Natarajan; Hiromi Imamichi; Mohamed R Boulassel; Michael M Lederman; Jean-Pierre Routy
Journal:  PLoS Pathog       Date:  2014-01-30       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.